Trial Profile
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Jul 2019
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CheckMate057
- Sponsors Bristol-Myers Squibb
- 01 Jul 2019 Results assesasing pharmacological cost of first- and second-line treatments with pembrolizumab, nivolumab and atezolizumab using 6 phase III trials (KEYNOTE-024, -010, CheckMate-026, 017, 057 and OAK) published in the Anticancer Research
- 22 May 2019 Results of Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients using data from 2 predominantly Chinese and 5 global studies, published in the Journal of Clinical Pharmacology
- 15 May 2019 Results of PPK analysis using data from multiple clinical studies in patients with AdjMEL, MEL, NSCLC, and other tumor types (CA209-001, CA209-003, CA209-005, CA209-017, CA209-057, CA209-037, CA209-066, CA209-238, CA209-063 and CA209-051) published in the Clinical Pharmacology and Therapeutics